NEW YORK – Kuur Therapeutics reported interim data on Thursday on its autologous GD2-targeting CAR NK-cell therapy, KUR-501, from a Phase I trial involving relapsed or refractory neuroblastoma patients.
NEW YORK – Kuur Therapeutics reported interim data on Thursday on its autologous GD2-targeting CAR NK-cell therapy, KUR-501, from a Phase I trial involving relapsed or refractory neuroblastoma patients.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.